Reassessment of Anti-CD20 Therapy in Lymphoid Malignancies: Impact, Limitations, and New Directions

This review will highlight the survival impact that rituximab therapy has had on major lymphoid malignancies, such as diffuse large B-cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, and mantle cell lymphoma. We will also discuss alternative anti-CD20 monoclonal antibodies.

Source: CancerNetwork - May 15, 2017 Category: Cancer & Oncology Authors: Jonathan W. Friedberg, MD, MMSc Patrick M. Reagan, MD Tags: Hematologic Malignancies Leukemia & Lymphoma Oncology Journal Review Article Source Type: news